In this Collaboratory, we will determine the efficacy of our leading therapeutic vaccines, bnMAbs, and LRAs in ART-suppressed, SHIV-infected monkeys and in ART-suppressed, HIV-1-infected humans. These studies will define optimal immunologic strategies for targeting the replication-competent viral reservoir, which is the critical barrier to HIV-1 eradication.

Dan Barouch, John Mellors, and Nelson Michael will serve as joint Principal Investigators of this Collaboratory. Dan Barouch has considerable expertise with translational preclinical-to-clinical development of HIV-1 vaccines and bnMAbs, conducting NHP studies and clinical trials, and leading large consortia. John Mellors has considerable expertise studying the viral reservoir, developing HIV-1 therapeutics, conducting clinical trials, and leading large consortia. Nelson Michael serves as Director of the U.S. Military HIV Research Program and has world-renowned expertise in the development and clinical evaluation of HIV-1 vaccine and cure strategies.

Additional senior investigators for this Collaboratory include: Galit Alter, Jintanat Ananworanich, Dennis Burton, Romas Geleziunas, Bette Korber, Rick Koup, John Mascola, Sharon Riddler, Charles Rinaldo, Hanneke Schuitemaker, Bob Siliciano, Bruce Walker, and Lu Zheng. Galit Alter and Dennis Burton are leading experts on neutralizing and non-neutralizing antibodies; Jintanat Ananworanich and Bruce Walker are leading the acutely treated cohorts in Thailand and South Africa; Romas Geleziunas leads the TLR7 agonist development program at Gilead; Bette Korber is a renowned theoretical biologist; Rick Koup and John Mascola lead the bnMAb development program at the VRC/NIH; Hanneke Schuitemaker leads the Ad26/MVA vaccine development program at Janssen; Sharon Riddler, John Mellors, and Charles Rinaldo lead the DC vaccine development program; Bob Siliciano is a world renowned expert on the viral reservoir; and Lu Zheng is an expert biostatistician for cure studies.